The Asia Pacific Sickle Cell Disease Treatment Market would witness market growth of 28.8% CAGR during the forecast period (2023-2030).
Growth of the market is also anticipated to be fuelled by the increasing approval of novel therapeutic medications for treating the condition. Additionally, rising government involvement in enhancing healthcare services and disease awareness is anticipated to fuel market expansion. The inaccessibility of medications in rural areas will present further possibilities for expanding the market in the coming years. Additionally, many hospitals and international organizations have also initiated several campaigns to raise awareness about hemoglobin deficiency.
The sickle cell disease pipeline consists of large pharmaceutical corporations with novel drugs in clinical trials and mid-sized and minor pharmaceutical companies with early-stage pipeline products. Due to the high efficacy of these treatments in early clinical studies, regulatory agencies have a favourable opinion of them, thereby aiding the rapid development of these medications by their vendors. Recent technological developments and the identification of sickle cell disease also fuel the strong pipeline for treating sickle cell disorders.
According to the International Trade Administration, China's healthcare sector grew strongly in 2018 and experienced dynamic regulatory change. China's demand for medical devices reached USD 78.81 billion. In 2018, sales of pharmaceutical and health products totalled USD 219.91 billion. The demand for medical devices has maintained a double-digit increase for over a decade, making it one of China's fastest-growing product sectors. Over 70% of this rise was attributed to hospital procurement. Access to improved medical facilities and specialized care has improved the diagnosis and treatment of SCD in the Asia-Pacific region.
The China market dominated the Asia Pacific Sickle Cell Disease Treatment Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $547.4 Million by 2030. The Japan market is registering a CAGR of 28% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 29.6% during (2023 - 2030).
Based on Treatment, the market is segmented into Blood Transfusion, Pharmacotherapy, and Bone Marrow Transplant. Based on End-Use, the market is segmented into Hospitals, Specialty Clinics and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Sickle Cell Disease Treatment Market is Projected to reach USD 7.3 Billion by 2030, at a CAGR of 27.9%
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Novartis AG, Pfizer Inc., bluebird bio, Inc., CSL Limited, Emmaus Life Sciences, Inc., Bristol Myers Squibb Company, CRISPR Therapeutics AG, Agios Pharmaceuticals, Inc. (LES LABORATOIRES SERVIER SAS), Novo Nordisk A/S and Medunik USA (Duchesnay Inc.).
Scope of the Study
Market Segments Covered in the Report:
By Treatment
- Blood Transfusion
- Pharmacotherapy
- Bone Marrow Transplant
By End-Use
- Hospitals
- Specialty Clinics
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Novartis AG
- Pfizer Inc.
- bluebird bio, Inc.
- CSL Limited
- Emmaus Life Sciences, Inc.
- Bristol Myers Squibb Company
- CRISPR Therapeutics AG
- Agios Pharmaceuticals, Inc. (LES LABORATOIRES SERVIER SAS)
- Novo Nordisk A/S
- Medunik USA (Duchesnay Inc.)
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Sickle Cell Disease Treatment Market, by Treatment
1.4.2 Asia Pacific Sickle Cell Disease Treatment Market, by End-Use
1.4.3 Asia Pacific Sickle Cell Disease Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Trials and Approvals
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2019, Feb – 2022, Jun) Leading Players
4.4 Porter Five Forces Analysis
Chapter 5. Asia Pacific Sickle Cell Disease Treatment Market by Treatment
5.1 Asia Pacific Blood Transfusion Market by Country
5.2 Asia Pacific Pharmacotherapy Market by Country
5.3 Asia Pacific Bone Marrow Transplant Market by Country
Chapter 6. Asia Pacific Sickle Cell Disease Treatment Market by End-use
6.1 Asia Pacific Hospitals Market by Country
6.2 Asia Pacific Specialty Clinics Market by Country
6.3 Asia Pacific Others Market by Country
Chapter 7. Asia Pacific Sickle Cell Disease Treatment Market by Country
7.1 China Sickle Cell Disease Treatment Market
7.1.1 China Sickle Cell Disease Treatment Market by Treatment
7.1.2 China Sickle Cell Disease Treatment Market by End-use
7.2 Japan Sickle Cell Disease Treatment Market
7.2.1 Japan Sickle Cell Disease Treatment Market by Treatment
7.2.2 Japan Sickle Cell Disease Treatment Market by End-use
7.3 India Sickle Cell Disease Treatment Market
7.3.1 India Sickle Cell Disease Treatment Market by Treatment
7.3.2 India Sickle Cell Disease Treatment Market by End-use
7.4 South Korea Sickle Cell Disease Treatment Market
7.4.1 South Korea Sickle Cell Disease Treatment Market by Treatment
7.4.2 South Korea Sickle Cell Disease Treatment Market by End-use
7.5 Singapore Sickle Cell Disease Treatment Market
7.5.1 Singapore Sickle Cell Disease Treatment Market by Treatment
7.5.2 Singapore Sickle Cell Disease Treatment Market by End-use
7.6 Malaysia Sickle Cell Disease Treatment Market
7.6.1 Malaysia Sickle Cell Disease Treatment Market by Treatment
7.6.2 Malaysia Sickle Cell Disease Treatment Market by End-use
7.7 Rest of Asia Pacific Sickle Cell Disease Treatment Market
7.7.1 Rest of Asia Pacific Sickle Cell Disease Treatment Market by Treatment
7.7.2 Rest of Asia Pacific Sickle Cell Disease Treatment Market by End-use
Chapter 8. Company Profiles
8.1 bluebird bio, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Research & Development Expenses
8.1.4 Recent strategies and developments:
8.1.4.1 Partnerships, Collaborations, and Agreements:
8.1.5 SWOT Analysis
8.2 CRISPR Therapeutics AG
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.2.4 Recent strategies and developments:
8.2.4.1 Partnerships, Collaborations, and Agreements:
8.2.5 SWOT Analysis
8.3 Agios Pharmaceuticals, Inc. (Les Laboratoires Servier SAS)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Research & Development Expenses
8.3.4 Recent strategies and developments:
8.3.4.1 Trials and Approvals:
8.3.5 SWOT Analysis
8.4 Medunik USA (Duchesnay Inc.)
8.4.1 Company Overview
8.4.2 Recent strategies and developments:
8.4.2.1 Trials and Approvals:
8.4.3 SWOT Analysis
8.5 CSL Limited
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 SWOT Analysis
8.6 Novo Nordisk A/S
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental & Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Acquisition and Mergers:
8.6.6 SWOT Analysis
8.7 Novartis AG
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Partnerships, Collaborations, and Agreements:
8.7.5.2 Trials and Approvals:
8.7.6 SWOT Analysis
8.8 Pfizer, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional & Segmental Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Acquisition and Mergers:
8.8.6 SWOT Analysis
8.9 Bristol Myers Squibb Company
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 SWOT Analysis
8.10. Emmaus Life Sciences, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 Recent strategies and developments:
8.10.4.1 Partnerships, Collaborations, and Agreements:
8.10.4.2 Product Launches and Product Expansions:
8.10.4.3 Trials and Approvals:
8.10.5 SWOT Analysis
TABLE 1 Asia Pacific Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 2 Asia Pacific Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Sickle Cell Disease Treatment Market
TABLE 4 Product Launches And Product Expansions– Sickle Cell Disease Treatment Market
TABLE 5 Acquisition and Mergers– Sickle Cell Disease Treatment Market
TABLE 6 Trials and Approvals- SICKLE Cell Disease Treatment Market
TABLE 7 Asia Pacific Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 8 Asia Pacific Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 9 Asia Pacific Blood Transfusion Market by Country, 2019 - 2022, USD Million
TABLE 10 Asia Pacific Blood Transfusion Market by Country, 2023 - 2030, USD Million
TABLE 11 Asia Pacific Pharmacotherapy Market by Country, 2019 - 2022, USD Million
TABLE 12 Asia Pacific Pharmacotherapy Market by Country, 2023 - 2030, USD Million
TABLE 13 Asia Pacific Bone Marrow Transplant Market by Country, 2019 - 2022, USD Million
TABLE 14 Asia Pacific Bone Marrow Transplant Market by Country, 2023 - 2030, USD Million
TABLE 15 Asia Pacific Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 16 Asia Pacific Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 17 Asia Pacific Hospitals Market by Country, 2019 - 2022, USD Million
TABLE 18 Asia Pacific Hospitals Market by Country, 2023 - 2030, USD Million
TABLE 19 Asia Pacific Specialty Clinics Market by Country, 2019 - 2022, USD Million
TABLE 20 Asia Pacific Specialty Clinics Market by Country, 2023 - 2030, USD Million
TABLE 21 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
TABLE 22 Asia Pacific Others Market by Country, 2023 - 2030, USD Million
TABLE 23 Asia Pacific Sickle Cell Disease Treatment Market by Country, 2019 - 2022, USD Million
TABLE 24 Asia Pacific Sickle Cell Disease Treatment Market by Country, 2023 - 2030, USD Million
TABLE 25 China Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 26 China Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 27 China Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 28 China Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 29 China Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 30 China Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 31 Japan Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 32 Japan Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 33 Japan Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 34 Japan Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 35 Japan Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 36 Japan Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 37 India Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 38 India Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 39 India Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 40 India Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 41 India Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 42 India Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 43 South Korea Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 44 South Korea Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 45 South Korea Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 46 South Korea Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 47 South Korea Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 48 South Korea Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 49 Singapore Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 50 Singapore Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 51 Singapore Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 52 Singapore Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 53 Singapore Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 54 Singapore Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 55 Malaysia Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 56 Malaysia Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 57 Malaysia Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 58 Malaysia Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 59 Malaysia Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 60 Malaysia Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 61 Rest of Asia Pacific Sickle Cell Disease Treatment Market, 2019 - 2022, USD Million
TABLE 62 Rest of Asia Pacific Sickle Cell Disease Treatment Market, 2023 - 2030, USD Million
TABLE 63 Rest of Asia Pacific Sickle Cell Disease Treatment Market by Treatment, 2019 - 2022, USD Million
TABLE 64 Rest of Asia Pacific Sickle Cell Disease Treatment Market by Treatment, 2023 - 2030, USD Million
TABLE 65 Rest of Asia Pacific Sickle Cell Disease Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 66 Rest of Asia Pacific Sickle Cell Disease Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 67 Key Information – bluebird bio, Inc.
TABLE 68 Key Information – CRISPR Therapeutics AG
TABLE 69 Key Information – Agios Pharmaceuticals, Inc.
TABLE 70 Key Information – Medunik USA
TABLE 71 Key Information – CSL Limited
TABLE 72 Key Information – Novo Nordisk A/S
TABLE 73 Key Information – Novartis AG
TABLE 74 Key Information – Pfizer, Inc.
TABLE 75 Key Information – Bristol Myers Squibb Company
TABLE 76 Key Information – Emmaus Life Sciences, INC.
List of Figures
FIG 1 Methodology for the research
FIG 2 Asia Pacific Sickle Cell Disease Treatment Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting Sickle Cell Disease Treatment Market
FIG 4 KBV Cardinal Matrix
FIG 5 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 6 Key Strategic Move: Partnerships, Collaborations & Agreements: 2019, Feb – 2022, Jun) Leading Players
FIG 7 Porter’s Five Forces Analysis – Sickle Cell Disease Treatment Market
FIG 8 Asia Pacific Sickle Cell Disease Treatment Market share by Treatment, 2022
FIG 9 Asia Pacific Sickle Cell Disease Treatment Market share by Treatment, 2030
FIG 10 Asia Pacific Sickle Cell Disease Treatment Market by Treatment, 2019 - 2030, USD Million
FIG 11 Asia Pacific Sickle Cell Disease Treatment Market share by End-use, 2022
FIG 12 Asia Pacific Sickle Cell Disease Treatment Market share by End-use, 2030
FIG 13 Asia Pacific Sickle Cell Disease Treatment Market by End-use, 2019 - 2030, USD Million
FIG 14 Asia Pacific Sickle Cell Disease Treatment Market share by Country, 2022
FIG 15 Asia Pacific Sickle Cell Disease Treatment Market share by Country, 2030
FIG 16 Asia Pacific Sickle Cell Disease Treatment Market by Country, 2019 - 2030, USD Million
FIG 17 SWOT Analysis: bluebird bio, Inc.
FIG 18 SWOT Analysis: CRISPR Therapeutics AG
FIG 19 SWOT Analysis: Agios Pharmaceuticals, Inc.
FIG 20 SWOT Analysis: Medunik USA
FIG 21 SWOT Analysis: CSL Limited
FIG 22 SWOT Analysis: Novo Nordisk A/S
FIG 23 Recent strategies and developments: Novartis AG
FIG 24 SWOT Analysis: Novartis AG
FIG 25 SWOT Analysis: Pfizer, Inc.
FIG 26 SWOT Analysis: Bristol Myers Squibb Company
FIG 27 Recent strategies and developments: Emmaus Life Sciences, Inc.
FIG 28 SWOT Analysis: Emmaus Life Sciences, Inc.